▁British 10.375
▁Bi 10.875
ote 5.59765625
ch 4.53515625
' 7.3671875
s 1.04296875
▁Can 5.2890625
cer 1.43359375
▁D 4.6640625
rug 3.82421875
▁Sh 8.015625
ows 3.69140625
▁Promise 10.1171875
, 6.4375
▁But 4.66015625
▁Anal 9.8984375
yst 2.826171875
s 2.037109375
▁Ur 8.7734375
ge 2.001953125
▁Ca 6.953125
ution 0.26123046875
<0x0A> 4.74609375
L 4.83984375
ON 5.546875
D 0.00429534912109375
ON 0.000156402587890625
▁- 3.4296875
▁In 4.14453125
▁a 1.7197265625
▁break 5.515625
through 0.2423095703125
▁development 5.1015625
, 1.15625
▁British 3.494140625
▁bi 4.0546875
ote 0.14501953125
ch 0.312744140625
▁firm 1.53125
▁Med 4.44921875
Gen 4.32421875
▁has 5.3828125
▁reported 4.31640625
▁encourag 7.4921875
ing 0.0024509429931640625
▁results 0.6962890625
▁for 2.66015625
▁its 0.7646484375
▁experimental 3.53125
▁cancer 2.353515625
▁drug 0.82177734375
, 1.11328125
▁M 2.923828125
G 0.64453125
X 2.841796875
- 0.298828125
1 1.2392578125
5 2.89453125
0 1.3798828125
, 1.693359375
▁during 5.265625
▁initial 5.32421875
▁clin 1.3525390625
ical 0.0018939971923828125
▁tri 0.33056640625
als 0.0006594657897949219
. 0.79052734375
▁While 5.5703125
▁these 4.19140625
▁find 3.654296875
ings 0.0002593994140625
▁have 2.291015625
▁gar 6.2890625
ner 2.276897430419922e-05
ed 0.0017080307006835938
▁significant 2.3359375
▁attention 1.1328125
▁among 3.201171875
▁research 3.611328125
ers 0.1666259765625
▁and 0.7880859375
▁patients 3.580078125
▁al 0.95751953125
ike 4.494190216064453e-05
, 0.06353759765625
▁anal 5.25
yst 0.0067291259765625
s 0.01068878173828125
▁are 1.822265625
▁ur 3.15625
ging 0.0120086669921875
▁ca 0.06243896484375
ution 0.00031113624572753906
▁until 3.98046875
▁further 2.056640625
▁data 2.228515625
▁establish 9.109375
es 0.65576171875
▁its 2.5
▁safety 3.021484375
▁and 0.295166015625
▁effic 0.3935546875
acy 0.00041365623474121094
. 0.3408203125
<0x0A> 0.20751953125
The 2.345703125
▁phase 6.3828125
▁ 1.4990234375
1 0.162109375
▁clin 1.4443359375
ical 0.0010576248168945312
▁trial 0.1710205078125
, 1.220703125
▁conducted 2.013671875
▁on 2.609375
▁a 2.822265625
▁small 1.4404296875
▁group 1.037109375
▁of 0.00800323486328125
▁patients 0.85205078125
▁with 1.0400390625
▁advanced 1.5205078125
- 3.453125
stage 0.032012939453125
▁can 2.328125
cers 0.0009870529174804688
▁such 4.0703125
▁as 0.00876617431640625
▁lung 2.265625
▁and 1.634765625
▁o 2.56640625
var 0.0238494873046875
ian 0.0005435943603515625
, 1.42578125
▁showed 2.7578125
▁that 0.98974609375
▁M 0.6708984375
G 0.0015106201171875
X 0.0221099853515625
- 0.00897979736328125
1 0.0017404556274414062
5 0.0018978118896484375
0 0.0006594657897949219
▁successfully 5.01171875
▁in 2.3359375
hib 0.005710601806640625
ited 0.14794921875
▁tum 1.560546875
or 0.1297607421875
▁growth 0.261962890625
▁in 1.2216796875
▁over 5.21484375
▁ 0.266845703125
6 2.271484375
0 0.154541015625
% 0.47314453125
▁of 0.01026153564453125
▁participants 2.50390625
. 0.60107421875
▁Moreover 4.6171875
, 0.002841949462890625
▁research 4.53125
ers 0.01439666748046875
▁observed 2.71484375
▁a 1.759765625
▁reduction 2.47265625
▁in 0.11871337890625
▁the 1.509765625
▁size 1.6455078125
▁of 0.1131591796875
▁tum 0.546875
ors 0.207763671875
▁in 0.77734375
▁ 1.49609375
4 2.013671875
0 1.0078125
% 0.11187744140625
▁of 0.0279998779296875
▁the 2.0078125
▁patients 0.771484375
, 1.326171875
▁mark 6.26953125
ing 0.0005106925964355469
▁a 0.88818359375
▁potentially 4.28515625
▁significant 1.232421875
▁adv 3.5
ancement 0.006298065185546875
▁in 0.498046875
▁the 0.716796875
▁on 4.72265625
going 0.5703125
▁battle 1.2734375
▁against 0.16943359375
▁cancer 0.241455078125
. 0.07647705078125
<0x0A> 0.27783203125
Dr 4.7265625
. 0.057159423828125
▁Em 6.5390625
ily 1.064453125
▁Dav 6.31640625
ies 0.501953125
, 0.170654296875
▁the 2.25390625
▁lead 1.755859375
▁research 0.806640625
er 0.00994110107421875
▁at 3.525390625
▁Med 0.93359375
Gen 0.01270294189453125
, 0.38232421875
▁expressed 3.236328125
▁c 4.515625
aut 0.0008587837219238281
ious 0.02435302734375
▁excitement 3.5078125
▁about 1.3759765625
▁the 0.2430419921875
▁find 2.333984375
ings 0.0001418590545654297
, 1.140625
▁stating 1.779296875
, 1.0390625
▁" 0.042144775390625
Wh 3.611328125
ile 0.032012939453125
▁the 1.8115234375
▁initial 2.490234375
▁data 1.888671875
▁from 2.40234375
▁the 1.78515625
▁trial 1.451171875
▁is 0.95751953125
▁prom 0.98388671875
ising 0.00016987323760986328
, 0.054779052734375
▁it 1.9521484375
▁is 0.6416015625
▁cru 3.916015625
cial 0.0167388916015625
▁to 0.69775390625
▁remember 3.76953125
▁that 0.045318603515625
▁this 1.5927734375
▁is 0.4130859375
▁only 1.767578125
▁the 1.005859375
▁first 0.185791015625
▁step 2.26171875
. 2.689453125
▁We 1.2783203125
▁need 1.5576171875
▁to 0.336181640625
▁conduct 2.53515625
▁further 1.68359375
▁studies 1.2353515625
▁to 0.55029296875
▁fully 3.736328125
▁understand 0.84912109375
▁the 0.392578125
▁drug 2.90234375
' 0.04632568359375
s 0.00028324127197265625
▁mechan 3.224609375
isms 0.0361328125
▁and 2.2734375
▁confirm 4.84375
▁its 0.55419921875
▁safety 1.029296875
▁and 0.77197265625
▁effic 0.18798828125
acy 4.1961669921875e-05
▁profile 6.953125
." 0.7060546875
<0x0A> 0.10009765625
The 2.390625
▁experimental 5.48828125
▁drug 0.62255859375
▁functions 7.71875
▁by 0.446044921875
▁target 1.9541015625
ing 0.003391265869140625
▁a 1.2548828125
▁specific 1.2578125
▁protein 1.1416015625
▁linked 5.91796875
▁to 0.057769775390625
▁the 1.5478515625
▁growth 0.98828125
▁and 1.0517578125
▁spread 0.479248046875
▁of 0.0614013671875
▁cancer 0.7001953125
▁cells 0.42919921875
. 0.322998046875
▁By 3.67578125
▁in 1.115234375
hib 0.005130767822265625
iting 0.0005764961242675781
▁this 0.63671875
▁protein 0.091064453125
, 0.25146484375
▁M 1.2294921875
G 0.0006070137023925781
X 0.0012645721435546875
- 0.00595855712890625
1 0.0010004043579101562
5 0.0008234977722167969
0 0.000518798828125
▁a 3.64453125
ims 0.062408447265625
▁to 0.0095672607421875
▁prevent 2.3125
▁the 1.7900390625
▁cells 3.64453125
▁from 0.08795166015625
▁pro 1.9189453125
l 0.0024242401123046875
ifer 0.00015366077423095703
ating 0.006946563720703125
▁and 0.77880859375
▁met 2.47265625
ast 0.0276947021484375
as 0.0084991455078125
izing 0.006893157958984375
, 0.93505859375
▁offering 6.28515625
▁potential 3.728515625
▁hope 3.193359375
▁for 0.86865234375
▁patients 1.033203125
▁in 3.388671875
▁advanced 2.333984375
▁stages 0.658203125
▁of 0.05145263671875
▁their 2.9765625
▁disease 1.3037109375
. 0.1024169921875
<0x0A> 0.44384765625
Des 3.62890625
p 0.0090179443359375
ite 4.124641418457031e-05
▁the 0.8154296875
▁initial 2.626953125
▁success 1.625
▁of 0.6904296875
▁M 1.6416015625
G 0.0005435943603515625
X 0.0014667510986328125
- 0.00356292724609375
1 0.000644683837890625
5 0.0007696151733398438
0 0.0004901885986328125
, 0.314697265625
▁exper 4.1640625
ts 3.123283386230469e-05
▁are 1.2529296875
▁rem 5.14453125
inding 0.042755126953125
▁the 2.232421875
▁public 0.61865234375
▁that 1.126953125
▁clin 4.01171875
ical 0.0034236907958984375
▁tri 0.1546630859375
als 4.0650367736816406e-05
▁are 0.61328125
▁a 3.203125
▁length 1.9384765625
y 0.003932952880859375
▁and 1.0166015625
▁met 5.64453125
icul 0.00011992454528808594
ous 0.04718017578125
▁process 0.058502197265625
. 0.96240234375
▁Dr 3.93359375
. 0.0092926025390625
▁Laura 6.9453125
▁Roberts 6.21875
, 0.2054443359375
▁a 0.81298828125
▁prominent 4.09375
▁on 0.84619140625
colog 0.458740234375
ist 0.0176544189453125
▁at 1.35546875
▁St 3.326171875
. 0.10955810546875
▁George 2.1875
' 0.0343017578125
s 0.0002307891845703125
▁Hospital 1.150390625
▁in 0.82421875
▁London 0.07489013671875
, 0.042938232421875
▁emphas 3.6171875
izes 2.99609375
▁the 0.7412109375
▁need 1.328125
▁for 0.158203125
▁vig 6.203125
il 0.03790283203125
ance 0.12353515625
. 2.5078125
▁" 0.46630859375
Wh 2.173828125
ile 0.009002685546875
▁these 2.25
▁pre 4.18359375
lim 0.00820159912109375
inary 0.0009889602661132812
▁results 0.60595703125
▁are 0.3037109375
▁encourag 1.26953125
ing 0.00048828125
, 0.0604248046875
▁it 1.35546875
▁is 0.341796875
▁important 0.7568359375
▁to 0.247802734375
▁recognize 3.4375
▁that 0.08221435546875
▁we 3.8671875
▁must 3.60546875
▁proceed 2.0
▁with 0.20703125
▁ca 0.1807861328125
ution 0.00012612342834472656
▁and 2.599609375
▁wait 2.564453125
▁until 2.759765625
▁we 2.587890625
▁have 0.41455078125
▁access 5.30078125
▁to 0.00373077392578125
▁more 1.181640625
▁data 1.181640625
▁from 2.44921875
▁larger 0.91259765625
- 2.8125
scale 0.036651611328125
▁tri 1.7001953125
als 1.3947486877441406e-05
," 1.22265625
▁she 0.305908203125
▁said 0.79638671875
. 0.0701904296875
<0x0A> 0.495849609375
The 2.658203125
▁bi 6.44140625
ote 0.01422882080078125
ch 0.11248779296875
▁industry 1.751953125
▁has 1.0302734375
▁experienced 3.146484375
▁previous 8.953125
▁instances 4.7109375
▁where 3.208984375
▁prom 1.8095703125
ising 0.00011360645294189453
▁dru 2.416015625
gs 1.7523765563964844e-05
▁have 1.0283203125
▁fal 6.59765625
tered 0.0009918212890625
▁during 2.236328125
▁later 3.228515625
▁stages 0.90625
▁of 0.049285888671875
▁clin 0.703125
ical 0.0007119178771972656
▁tri 0.20458984375
als 0.0005970001220703125
. 0.30029296875
▁The 3.068359375
▁path 8.6796875
▁to 0.65185546875
▁commercial 2.478515625
ization 0.39599609375
▁is 1.2841796875
▁often 1.81640625
▁imp 7.81640625
eded 0.08197021484375
▁by 0.1495361328125
▁un 3.443359375
for 0.9052734375
ese 0.007488250732421875
en 0.01065826416015625
▁comp 2.76953125
lications 0.0022754669189453125
, 0.98828125
▁such 1.9345703125
▁as 0.0027370452880859375
▁unf 5.5703125
avor 0.05694580078125
able 0.00200653076171875
▁side 2.328125
▁effects 0.12744140625
▁or 0.95556640625
▁lack 3.158203125
l 2.162109375
uster 0.007396697998046875
▁performance 4.203125
▁in 0.8974609375
▁larger 1.1201171875
▁patient 5.2734375
▁populations 0.6748046875
. 0.039276123046875
▁Con 5.8125
sequently 0.07122802734375
, 0.0005764961242675781
▁many 2.919921875
▁prom 3.2578125
ising 0.00019752979278564453
▁ther 3.333984375
ap 0.0016241073608398438
ies 8.392333984375e-05
▁fail 2.6796875
▁to 0.13720703125
▁gain 2.259765625
▁necessary 5.77734375
▁appro 1.08203125
val 8.20159912109375e-05
s 1.5537109375
▁for 2.625
▁bro 4.7109375
ader 0.0011081695556640625
▁use 0.548828125
. 0.53271484375
<0x0A> 0.193115234375
Anal 4.04296875
yst 0.003620147705078125
s 0.01279449462890625
▁echo 6.62890625
▁the 1.556640625
▁c 4.14453125
aut 0.00047969818115234375
ious 0.01128387451171875
▁optim 1.4658203125
ism 0.0008254051208496094
▁exhib 4.9375
ited 0.0002548694610595703
▁by 0.0220794677734375
▁medical 4.5
▁exper 1.43359375
ts 1.0251998901367188e-05
. 0.85888671875
▁" 1.0419921875
Wh 1.966796875
ile 0.004001617431640625
▁initial 2.947265625
▁data 1.990234375
▁suggests 3.25390625
▁potential 4.734375
, 2.484375
▁it 1.388671875
▁would 4.91796875
▁be 0.10589599609375
▁impr 3.125
udent 0.00079345703125
▁to 0.0948486328125
▁over 3.32421875
look 2.009765625
▁the 0.439697265625
▁hur 5.94140625
d 2.1457672119140625e-05
les 0.017303466796875
▁still 3.732421875
▁facing 2.6015625
▁M 0.85595703125
G 0.0011806488037109375
X 0.00281524658203125
- 0.0176239013671875
1 0.0005650520324707031
5 0.00031113624572753906
0 0.00069427490234375
," 0.63330078125
▁commented 3.21484375
▁Rach 7.31640625
el 0.1270751953125
▁Wilson 5.9609375
, 0.16455078125
▁a 1.271484375
▁ph 3.556640625
arma 0.01206207275390625
ce 0.056610107421875
ut 6.318092346191406e-06
ical 0.0007805824279785156
▁industry 2.4140625
▁anal 0.34814453125
yst 2.288818359375e-05
▁at 0.57666015625
▁Bern 5.83203125
stein 0.00807952880859375
. 0.65869140625
▁" 0.241455078125
It 2.73046875
▁is 0.82470703125
▁cru 1.7373046875
cial 0.00582122802734375
▁to 0.65380859375
▁not 6.94140625
▁get 3.60546875
▁carried 2.337890625
▁away 0.001255035400390625
▁until 4.53515625
▁more 2.421875
▁compreh 4.36328125
ensive 0.0008473396301269531
▁clin 2.74609375
ical 0.0007238388061523438
▁trial 1.7734375
▁results 1.0859375
▁are 0.320556640625
▁available 1.408203125
." 0.697265625
<0x0A> 0.08343505859375
Med 2.376953125
Gen 0.04229736328125
, 2.501953125
▁a 1.291015625
▁relatively 6.35546875
▁small 2.08203125
▁bi 0.316162109375
ote 0.0108795166015625
ch 0.092041015625
▁firm 0.494140625
, 0.62109375
▁has 1.115234375
▁seen 4.3984375
▁its 1.1767578125
▁stock 0.84130859375
▁so 3.2265625
ar 0.0020999908447265625
▁in 1.2578125
▁recent 0.595703125
▁days 2.759765625
▁as 2.037109375
▁news 3.107421875
▁of 0.120849609375
▁M 2.935546875
G 0.0006871223449707031
X 0.0059967041015625
- 0.0044708251953125
1 0.0005135536193847656
5 0.00039839744567871094
0 0.0005536079406738281
' 0.141845703125
s 0.00015342235565185547
▁initial 2.009765625
▁success 0.72412109375
▁spread 1.2724609375
. 0.7646484375
▁However 2.927734375
, 0.00806427001953125
▁financial 5.09375
▁anal 0.5478515625
yst 0.0003619194030761719
s 0.006603240966796875
▁warn 1.91015625
▁that 0.6591796875
▁this 3.447265625
▁spec 7.98046875
ulative 0.1571044921875
▁enthus 6.15625
ias 0.00020551681518554688
m 1.7642974853515625e-05
▁may 1.4892578125
▁be 1.1484375
▁prem 1.0517578125
ature 6.818771362304688e-05
. 0.399658203125
▁A 5.921875
▁single 5.8828125
▁prom 2.837890625
ising 0.00028705596923828125
▁drug 3.0078125
▁is 2.1171875
▁far 3.509765625
▁from 0.07781982421875
▁a 1.23046875
▁guaranteed 3.328125
▁path 3.314453125
way 2.658203125
▁to 0.07989501953125
▁commercial 2.06640625
▁success 0.54931640625
, 0.958984375
▁and 0.666015625
▁the 2.01171875
▁current 4.9765625
▁excitement 5.0625
▁may 1.66015625
▁actually 5.48046875
▁h 2.76171875
inder 0.0045623779296875
▁Med 1.8583984375
Gen 0.0022449493408203125
' 0.1297607421875
s 0.00011682510375976562
▁ability 0.9326171875
▁to 0.001739501953125
▁secure 2.224609375
▁further 3.3046875
▁fund 0.487548828125
ing 0.001377105712890625
▁to 2.94921875
▁ensure 5.48046875
▁the 0.97021484375
▁drug 1.205078125
' 0.0953369140625
s 0.0001348257064819336
▁development 3.109375
. 0.62451171875
<0x0A> 0.139892578125
Des 5.41015625
p 0.01557159423828125
ite 0.0003616809844970703
▁the 0.9384765625
▁c 3.634765625
aut 0.0019702911376953125
ious 0.013275146484375
▁sentiment 6.2421875
, 0.70263671875
▁many 3.0234375
▁cancer 6.234375
▁patients 0.4052734375
▁and 2.171875
▁their 1.990234375
▁families 0.97509765625
▁are 0.62548828125
▁hoping 3.87109375
▁that 1.1767578125
▁M 0.64990234375
G 0.0002713203430175781
X 0.000858306884765625
- 0.0019931793212890625
1 0.0005030632019042969
5 0.00028324127197265625
0 0.0003345012664794922
▁will 0.763671875
▁eventually 3.533203125
▁offer 2.892578125
▁a 1.3037109375
▁treatment 4.19921875
▁option 1.7109375
▁for 1.1484375
▁those 1.998046875
▁batt 2.751953125
ling 0.0003654956817626953
▁this 2.4296875
▁dead 1.4833984375
ly 0.0006985664367675781
▁disease 0.057464599609375
. 0.0113677978515625
▁Med 4.51171875
Gen 0.0065765380859375
▁plans 4.80078125
▁to 0.03289794921875
▁initi 4.515625
ate 6.949901580810547e-05
▁further 2.732421875
▁tri 2.310546875
als 5.0902366638183594e-05
▁involving 5.91015625
▁larger 1.0
▁patient 0.1571044921875
▁groups 1.9111328125
▁next 4.4765625
▁year 0.1719970703125
, 0.599609375
▁int 8.640625
ending 0.00540924072265625
▁to 0.0196685791015625
▁provide 3.3984375
▁a 2.109375
▁more 1.1708984375
▁compreh 1.458984375
ensive 0.0006737709045410156
▁understanding 2.75
▁of 0.0097808837890625
▁the 0.5419921875
▁drug 0.43310546875
' 0.03521728515625
s 8.7738037109375e-05
▁potential 1.91796875
▁benefits 2.078125
▁and 0.95654296875
▁side 1.458984375
▁effects 0.0194091796875
. 0.082763671875
<0x0A> 0.2490234375
The 3.451171875
▁road 7.1484375
▁to 0.8681640625
▁finding 5.94921875
▁effective 3.357421875
▁cancer 1.09765625
▁treat 0.49658203125
ments 4.863739013671875e-05
▁is 0.7548828125
▁long 0.8701171875
▁and 0.25439453125
▁ar 1.650390625
du 0.00014519691467285156
ous 9.453296661376953e-05
, 0.5380859375
▁but 0.6689453125
▁the 2.1484375
▁early 3.349609375
▁signs 1.7294921875
▁of 1.1357421875
▁progress 2.9140625
▁demonstrated 8.1484375
▁by 0.09228515625
▁Med 1.8203125
Gen 0.0017070770263671875
' 1.3662109375
s 0.00023698806762695312
▁M 1.19140625
G 0.00033473968505859375
X 0.002910614013671875
- 0.001873016357421875
1 0.0004756450653076172
5 0.00018477439880371094
0 0.00021564960479736328
▁are 1.087890625
▁und 4.53125
ou 2.2109375
bt 0.002735137939453125
edly 0.0062255859375
▁worth 5.20703125
▁acknowled 7.38671875
ging 0.007213592529296875
. 0.0535888671875
▁As 2.845703125
▁the 1.1875
▁scientific 4.74609375
▁community 0.1658935546875
▁eager 5.078125
ly 0.0002562999725341797
▁a 0.2685546875
wa 3.0875205993652344e-05
its 6.079673767089844e-06
▁more 2.78515625
▁extensive 5.46484375
▁results 2.037109375
, 0.9931640625
▁anal 2.03125
yst 7.939338684082031e-05
s 0.000545501708984375
, 5.8828125
▁research 2.546875
ers 0.0069122314453125
, 0.1990966796875
▁and 0.07159423828125
▁patients 0.359375
▁are 3.49609375
▁rem 3.337890625
ind 0.051025390625
ed 1.823902130126953e-05
▁that 1.353515625
▁the 1.8662109375
▁journey 2.91796875
▁to 0.8525390625
▁a 1.3017578125
▁vi 5.09765625
able 0.00014328956604003906
▁cancer 1.357421875
▁drug 2.091796875
▁is 0.70654296875
▁one 4.578125
▁that 0.658203125
▁dem 5.3828125
ands 2.9087066650390625e-05
▁p 0.78076171875
atience 2.682209014892578e-05
, 1.2275390625
▁pers 2.53515625
istence 0.01039886474609375
, 0.02496337890625
▁and 0.0081939697265625
▁res 7.03125
ili 0.08123779296875
ence 5.4836273193359375e-06
. 0.05389404296875
